OPKO Health (OPK) Projected to Post Quarterly Earnings on Thursday

OPKO Health (NASDAQ:OPK) is projected to post its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect OPKO Health to post earnings of ($0.07) per share and revenue of $139.7570 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

OPKO Health Stock Performance

OPK opened at $1.22 on Thursday. The firm’s 50 day moving average is $1.29 and its 200-day moving average is $1.36. OPKO Health has a 52-week low of $1.11 and a 52-week high of $2.04. The company has a quick ratio of 3.32, a current ratio of 3.70 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $936.59 million, a P/E ratio of -4.88 and a beta of 1.47.

Insider Transactions at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 580,000 shares of OPKO Health stock in a transaction on Friday, November 21st. The stock was bought at an average price of $1.33 per share, for a total transaction of $771,400.00. Following the transaction, the chief executive officer owned 216,706,448 shares of the company’s stock, valued at $288,219,575.84. The trade was a 0.27% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 49.69% of the company’s stock.

Institutional Trading of OPKO Health

Hedge funds and other institutional investors have recently modified their holdings of the company. EP Wealth Advisors LLC purchased a new position in OPKO Health in the 4th quarter worth about $37,000. XTX Topco Ltd acquired a new position in OPKO Health in the 4th quarter valued at approximately $432,000. Zacks Investment Management purchased a new stake in OPKO Health in the 4th quarter worth approximately $27,000. Quadrature Capital Ltd purchased a new stake in OPKO Health in the 4th quarter worth approximately $116,000. Finally, Millennium Management LLC acquired a new stake in shares of OPKO Health during the 4th quarter valued at $334,000. Institutional investors own 64.63% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on OPK. Barrington Research reiterated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a report on Thursday, October 30th. Wall Street Zen upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Sunday, December 21st. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday, January 22nd. Jefferies Financial Group reiterated a “hold” rating and issued a $1.60 target price (down previously from $2.00) on shares of OPKO Health in a research report on Thursday, October 30th. Finally, JPMorgan Chase & Co. started coverage on OPKO Health in a research report on Thursday, November 20th. They set a “neutral” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $2.28.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.